Endra Life Sciences Inc. · NASDAQ:NDRA

Endra Life Sciences — Investor Presentation (September 2020)

16 slides from Endra Life Sciences's investor presentation, Sep 2, 2020

  1. Slide 1: Addressing the Need in Liver Disease (NAFLD-NASH) Assessment

    Addressing the Need in Liver Disease (NAFLD-NASH) Assessment INVESTOR PRESENTATION SEPTEMBER 2020 ENDRA LIFE SCIENCES ‘NASDAQ: NORA

  2. Slide 2: Safe Harbor

    Safe Harbor Cras tates ale i resetaten alr eg seme Herat her th sures hte nadir ng snes rear ten how ea al cr satay Mareen tra pestn tre rere propel cat preps. ps obec el maar afer pov aware tenes fernrd key tment grb are eects reat hares Yue rary tet al eaten by eile th "prams" "peepee" ‘esiete” "r

  3. Slide 3: ENDRA Life Sciences Snapshot

    ENDRA Life Sciences Snapshot GOAL: VISUALIZE HUMAN TISSUE LIKE MRI ... AT SOX LOWER COST! & POINT OF PATIENT CARE © © ~Wemployees Fla application: Liver Leadership advisors, 6 Plug-and-play maging platform disease (NAFLO-KASH) affecting | Based in Ann Arbor. Michigan. partners from GE with 18 bilion

  4. Slide 4: Focused on a Large and Rapidly Growing Market: NAFLD-NASH

    Focused on a Large and Rapidly Growing Market: NAFLD-NASH TOTAL ANNUAL DIRECT MEDICAL COSTS IN U.S. FOR NAFLD: ~$103B? Liver Disease: NAFLD-NASH Diagnastic Gap f* Therapies Near Ibillion+ people affected? Linked to obesity, Current diagnastc tons nat practical Advent of first targeted therapies for

  5. Slide 5: Measuring Liver Fat in NAFLD-NASH Patients

    Measuring Liver Fat in NAFLD-NASH Patients CURRENTLY NO PRACTICAL & RIGOROUS TOOL FOR STAGING STEATOSIS OPTIMAL BALANCE x DIAGNOSTIC VALUE 2 Low Low ACCESSIBILITY HIGH (Denona (AFFORDABILITY, SAFETY, EASE OF USE) signe: 3s

  6. Slide 6: Total Addressable Market for NAFLD-NASH Fat Measurement Tool

    Total Addressable Market for NAFLD-NASH Fat Measurement Tool $1 BILLION OPPORTUNITY ... WITH UPSIDE Estimated 2019 Number of Facilities’ Facilities (hospitals. clinics, private practices) currently doing 20,000 Performing Abdominal-Liver Ultrasound Scans :~-* —_abdo-liver ultrasound scans, who could

  7. Slide 7: Solution: Thermo Acoustic Enhanced UltraSound (TAEUS)

    Solution: Thermo Acoustic Enhanced UltraSound (TAEUS*) RF SIGNALS QUANTITATE LIVER FAT FRACTION ‘Secured 80 19485 Certification Y Completed first human feasibility study (N=I9) + Sensitivity 188 Specificity 182 AUROC 0. MRL-POFF 6% steatosis Dbtained CE Mark: European regulatory approval Y Protected

  8. Slide 8: TAEUS Platform Evolution

    TAEUS’ Platform Evolution: MULTIPLE POTENTIAL CLINICAL APPLICATIONS & REVENUE STREAMS TO SCALE BUSINESS HARDWARE SOFTWARE DISPOSABLES LICENSING isc rng ety MISS lle syle ptsoehnce TIS win fee OO . MS acer lcesng TS perme a, rid pes) tegued sens pris Se ‘yea red ‘VASCULAR FLOW - Future S18 bilont TAE

  9. Slide 9: ENDRA 2020 Milestones: Liver Application

    ENDRA 2020 Milestones: Liver Application SECURE REGULATORY APPROVALS AND INSTALL FIRST COMMERCIAL SYSTEMS, {H'20 2420 Y Obtain CE Mark certification Announce atonal EU 6 US evaluation sites Y id hepatology influence to ENORA clinical advisory Execute controlled launch in EU with early adopters & sma

  10. Slide 10: ENDRA Partners

    ENDRA Partners SUPPORTING TECHNICAL, CLINICAL & COMMERCIAL DEVELOPMENT OF TAEUS @ GE Healthcare Strategic partnership + Supports product development & introductions to GE ultrasound customers: * BE option fort year sales exclusivity on TAEUS liver application and other rights (DENRA Clinical evaluat

  11. Slide 11: Commercialization: Targeting High Value Clinical Segments

    Commercializati : Targeting High Value Clinical Segments BUILD AWARENESS AND CLINICAL EVIDENCE & DEPLOY LOCAL TACTICS IMAGING EXPERTS __LIVEREXPERTS METABOLISM & ENDRA COMMERCIAL APPROACH jology __ Gastro-Hepatology LIFESTYLE EXPERTS be) ENORA @ key Clinical sono aa Virtual booths, onlin IE : : 0 pr

  12. Slide 12: Leadership

    Leadership MANAGEMENT Francois Michelon Michael Thornton ‘harman 8080 cia I yersiameb tech (Syersmedtoc Eteaticare Smith Nepten, fader heed Bonet Visnstens old 068) INDEPENDENT DIRECTORS Sam Gambhir, MD, PhD Michael Harsh fod SCIENTIFIC ADVISORS (Deno el Teh Or Ret) BE ears Jing Gao, MO Weil Corel M

  13. Slide 13: ENDRA Investment Highlights

    ENDRA Investment Highlights Addressing clear unmet need inlver disease (NAFLDAASH), KEY STATISTICS (as of tugs 282020) Hering eae Cash Balance 40M Aged with advent of fst targeted NAFLO-NASH therapies ecindemayane Common Stock rice (NASOAD NORA) 3082 ies Common Shares Outstanding AM Blu-chp commerci

  14. Slide 14: ENDRA

    ENDRA

  15. Slide 15: Liver Fat Measurement Tools: Relative Performance & Accessibility

    Liver Fat Measurement Tools: Relative Performance & Accessibility ‘i é - eT are ce er parecer) 1 See trad dome eo Sn rer ae Napanee ge a ew cy ae 1 Nite fad pen a BL emieneny + Settee i Femtroncon amine eh + ay ede ae Co ry - $s Nirman 2 0 octet re de anette neat cit natn + int pore Cr + Pa srrerena

  16. Slide 16: Sources & Assumptions

    Sources & Assumptions | XN rene preteen pe 1 lew mre ee ry pe a ne ‘ent aha Sr nag th om nye Somer btittre 1 heey Danone rl ney edema ew a ‘te won i Bren 8 (Phat ln po i PAGES 1 ps enn es rd dey rd hep "eu 2 eer re yt i Pc Oh ep pe tin bo ‘teppei ose Ear ee Fae sovpisnrnenereen itera ior ery ow or a

ENDRA Life Sciences — Investor Presentation (September 2020) on 6ix